Zevra Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 69
- Market Cap
- $379.3M
- Website
- http://zevra.com
- Introduction
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Healthy Returns: FDA approvals fall in 2024
The FDA approved 50 new drugs in 2024, including first-ever treatments for MASH and Niemann-Pick disease type C, and novel therapies for schizophrenia, hemophilia, and pulmonary arterial hypertension. Notable approvals include Rezdiffra, Miplyffa, Aqneursa, Cobenfy, Hympavzi, Winrevair, and Imdelltra. Smaller biotech companies are increasingly bringing products to market independently.
Healthy Returns: FDA approvals fall in 2024, Transcarent acquires Accolade
The FDA approved 50 new drugs in 2024, including first-ever treatments for MASH and Niemann-Pick disease type C, and novel therapies for schizophrenia, hemophilia, pulmonary arterial hypertension, and small-cell lung cancer. Many approvals were from smaller biotech firms, indicating a shift towards independent market entry. Transcarent announced a $621M acquisition of Accolade, aiming to enhance personalized healthcare.
NeurologyLive Year in Review 2024: Top Stories in Sleep Disorders
In 2024, NeurologyLive® highlighted neurology advancements, focusing on sleep disorders. Key updates included FDA approvals for narcolepsy treatments, promising phase 3 trial results for sleep apnea, and a deep learning model predicting cognitive status from sleep EEG data. Light therapy showed benefits for Alzheimer's disease symptoms.
Sleep Medicine Year in Review: 2024
2024 marked significant advancements in sleep medicine, including FDA approvals for tirzepatide for OSA in obesity, sodium oxybate for pediatric narcolepsy, and pitolisant for EDS in children. Updated RLS guidelines advised against dopamine agonists, favoring iron therapies and alpha 2 delta ligands. Phase 2 trials of KP1077 showed promise for idiopathic hypersomnia. Sleep health in dialysis and long COVID patients highlighted the need for tailored treatments. Experts advocated against daylight-saving time, citing health risks.
Year in review: Major medical breakthroughs of 2024 that you must know
2024 saw major medical advancements: FDA approved Orlynvah for UTIs, Cobenfy for schizophrenia, and Miplyffa/Aqneursa for Niemann-Pick disease type C. Bayer's elinzanetant showed promise for hot flashes.
2024: A Year of Cautious IPOs, Restraint and Breakthroughs
In 2024, biotech IPOs remained limited, with companies struggling post-debut. M&A activity was tepid, with notable deals like Novo Holdings' $16.5B Catalent merger. Novartis' $1.1B acquisition of Kate Therapeutics highlighted early-stage science's appeal. Neuroscience, GLP-1s, radiopharma, and antibody-drug conjugates were key topics. An Alzheimer’s drug and RSV vaccines marked progress. The industry remains in a downturn, with hopes for diverse breakthroughs in 2025.
Zevra Therapeutics to be added to Nasdaq Biotechnology Index
Zevra Therapeutics (ZVRA) to be added to the Nasdaq Biotechnology Index (NBI) on Dec 23, 2024, as part of the 2024 Nasdaq indexes reconstitution.
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index Effective ...
Zevra Therapeutics to be added to the Nasdaq Biotechnology Index on Dec 23, 2024, reflecting its progress in rare disease treatment.
Zevra Therapeutics Secures Coveted Spot in Nasdaq Biotechnology Index Following ...
Zevra Therapeutics (ZVRA) announced its addition to the Nasdaq Biotechnology Index (NBI) effective December 23, 2024, reflecting its eligibility requirements like minimum market cap, average daily trading volume, and biotechnology industry classification. The NBI tracks biotech and pharma securities on Nasdaq under a modified capitalization-weighted methodology, raising Zevra's profile among biotech funds and portfolio managers.
© Copyright 2025. All Rights Reserved by MedPath